What is the current Price Target for the Talis Biomedical Corp stock?

The average Talis Biomedical Corp target price is $5.10. This is 240.00% higher than the current stock price. The highest price target is 250.00%, the lowest is 236.67%. 3 Analysts have issued a price target Talis Biomedical Corp 2026 .

How high will the Talis Biomedical Corp stock rise?

No reliable answer can be given as to how high the Talis Biomedical Corp stock will rise. The performance of stocks, including the Talis Biomedical Corp stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Talis Biomedical Corp stock today?

The performance of Talis Biomedical Corp stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Talis Biomedical Corp stock fall?

The decline in Talis Biomedical Corp stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Talis Biomedical Corp Forecast, price target & analysts

$1.50

0.00%

Nasdaq, Aug 08, 03:30 pm CET

ISIN

US87424L1089

Symbol

TLIS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Overview Dividends Analysts Charts Strategies

Talis Biomedical Corp Target price 2025 - Analyst rating & recommendation

Talis Biomedical Corp Classifications & Recommendation:

Hold

33%

Sell

67%

Talis Biomedical Corp Price Target

Target Price	$5.10
Price	$1.50
Potential	240.00% register free of charge
Number of Estimates	3

	3 Analysts have issued a price target Talis Biomedical Corp 2026 . The average Talis Biomedical Corp target price is $5.10. This is 240.00% register free of charge higher than the current stock price. The highest price target is $5.25 250.00% register free of charge , the lowest is $5.05 236.67% register free of charge .
	A rating was issued by 6 analysts: 0 Analysts recommend Talis Biomedical Corp to buy, 2 to hold and 4 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Talis Biomedical Corp stock has an average upside potential 2026 of 240.00% register free of charge . Most analysts recommend the Talis Biomedical Corp stock at Sale.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '23	2024 Estimates
Earnings Per Share $	-34.12	-23.79
	46.39%	30.28%
P/E		negative

3 Analysts have issued a Talis Biomedical Corp forecast for earnings per share. The average Talis Biomedical Corp EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2023. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2023	$-34.12	46.39%
2024	$-23.79 30.28% Unlock
2025	$-28.34 19.13% Unlock

Current	-0.05	60.13%
2024	-0.06 12.15% Unlock
2025	-0.05 16.67% Unlock

Talis Biomedical Corp...

Discover more stocks with a high price target

Deutsche Telekom 29.37%

BioNTech SE - ADR 28.36%

Alibaba Group Holding Ltd 27.69%

PayPal 25.45%

Walt Disney 22.35%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now